KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Account Payables: 2016-2024

Historic Change in Account Payables for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$69.0 million.

  • Moderna's Change in Account Payables fell 7.29% to $89.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.0 million, marking a year-over-year increase of 2.44%. This contributed to the annual value of -$69.0 million for FY2024, which is 630.77% down from last year.
  • Per Moderna's latest filing, its Change in Account Payables stood at -$69.0 million for FY2024, which was down 630.77% from $13.0 million recorded in FY2023.
  • Over the past 5 years, Moderna's Change in Account Payables peaked at $240.0 million during FY2022, and registered a low of -$69.0 million during FY2024.
  • Its 3-year average for Change in Account Payables is $61.3 million, with a median of $13.0 million in 2023.
  • As far as peak fluctuations go, Moderna's Change in Account Payables skyrocketed by 1,600.00% in 2021, and later crashed by 630.77% in 2024.
  • Yearly analysis of 5 years shows Moderna's Change in Account Payables stood at $12.0 million in 2020, then skyrocketed by 1,600.00% to $204.0 million in 2021, then rose by 17.65% to $240.0 million in 2022, then slumped by 94.58% to $13.0 million in 2023, then plummeted by 630.77% to -$69.0 million in 2024.